Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07678931 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Trial sites expanded: 1 → 27 locations
    • Start date changed from estimate of Aug 2026 to Aug 13, 2026
    • Secondary endpoints: details revised at 12 of 18 entries
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the quality of life, Pharmakokinetics(PK), Pharmacodynamics (PD) characteristics, and immunogenicity of subjects.
Trial Details
NCT Number NCT07678931
Lead Sponsor Chengdu Kangnuoxing Biopharma,Inc.
Conditions
(from sponsor)		 Seasonal Allergic Rhinitis (SAR)
Related terms Rhinitis, Allergic, Seasonal
Enrollment 136 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov